Binding agents dextrin

In Aronson s composition a small jHioportion of potassium oxy-salts arc used with a rcJativdy large proportion of ph phorus mixed with an equal proportion of lamp-black or other sK>n-glowtng material, and binding agent (dextrin). 

Dextrine does not have a large cohesive power with the consequence that it is not widely used as the binding agent of firework compositions in Japan, but it is used as the combustion agent for coloured smoke compositions When it comes in contact with heated potassium chlorate, it reacts with the hlorate at 3 2°C, which is higher than that of milk or cane sugar Dextrine burns more easily than starch ... 

Bandyopadhyay AK, Chaudhuri B, Bhattacharjee PK. Starch paste granulation I effect of dextrinized corn starch mucilage as binding agent on granulation and tablet quality. Aust J Pharm Sci 1980 9(3) 85-89. 

The antiviral properties of anionic polymers have recently received a lot of attention as agents to protect against infection with sexually transmitted diseases. Due to the cationic nature of most viruses, several anionic polymers are known to bind viruses. As early as the 1960s, researchers had studied the anti-viral properties of a variety of synthetic polymers [118]. However, not all anionic polymers inactivate viruses. Several classes of anionic polymers have been studied for their ability to inactivate the HIV virus. These polymers include poly(styrene-4-sulfonate), 2-naphthalenesulfonate-formaldehyde polymer, and acrylic acid-based polymers. Certain chemically modified natural polymers (i.e., semisynthetic) such as dextrin/dextran sulfates, cellulose sulfate, carrageenan sulfate, and cellulose acetate phthalate have also been investigated for this purpose. Of a number of such anionic polymers that have shown in-vitro and in vivo anti-HIV activity, a couple of polymeric drug candidates have proceeded to early stage human clinical trials for the evaluation of safety/tolerability [119]. While most of these have shown the desired tolerability and safety, further clinical trials are necessary to discern the therapeutic benefit and see if anionic polymers will be applicable as anti-HIV therapies. 

---